Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atara Biotherapeutics (ATRA)
NASDAQ:ATRA
RESEARCH TOOLSreports
Atara Biotherapeutics (ATRA) Stock Price & Analysis
1,046 Followers
ATRA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.20 - $2.54
Previous Close$0.61
Volume1.82M
Average Volume (3M)1.67M
Market Cap
$73.45M
Enterprise Value$19.55M
Total Cash (Recent Filing)$102.41M
Total Debt (Recent Filing)$48.51M
Price to Earnings (P/E)-0.3
Beta2.34
Next Earnings
Aug 05, 2024EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.12
Shares Outstanding120,416,138
10 Day Avg. Volume1,596,827
30 Day Avg. Volume1,674,858
Standard Deviation0.26
R-Squared0.02
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-0.75
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.32
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$4.18Price Target Upside585.25% Upside
Rating ConsensusHold
Number of Analyst Covering5
Atara Biotherapeutics News
PremiumCompany Announcements
Atara Biotherapeutics Board Member Decides Not to Seek Re-Election
PremiumCompany Announcements
Atara Biotherapeutics Restructures, CMO Transitions to Consultant
Bulls Say, Bears Say
Bulls Say
Financial ForecastVarious CAR-T products, with likely the next key inflection coming from ATA3219, are projected to contribute to a robust CAR-T platform, potentially reaching up to $1Bn in peak sales.
PartnershipAtara receives meaningful upfront cash in connection with the closure of the expanded global partnership with Pierre Fabre.
Regulatory MilestoneConcordance with U.S. regulators on tab-cel BLA requirements supports Atara's ability to pool the pivotal clinical trial data.
Bears Say
Clinical Trial OutcomeThe trial failed, with no discernible trend, suggesting a worst-case scenario outcome.
Financial HealthDespite cash reserves from the Pierre Fabre deal, investor confidence may wane due to ongoing operational expenditures and a tough market environment.
Regulatory RiskRisks include, but are not limited to: rejection of the tab-cel BLA by the FDA.
---
Ownership Overview
10.74% Insiders
19.90% Mutual Funds
35.55% Other Institutional Investors
33.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATRA FAQ
What was Atara Biotherapeutics’s price range in the past 12 months?
Atara Biotherapeutics lowest stock price was $0.20 and its highest was $2.54 in the past 12 months.
What is Atara Biotherapeutics’s market cap?
Currently, no data Available
When is Atara Biotherapeutics’s upcoming earnings report date?
Atara Biotherapeutics’s upcoming earnings report date is Aug 05, 2024 which is in 78 days.
How were Atara Biotherapeutics’s earnings last quarter?
Atara Biotherapeutics released its earnings results on May 08, 2024. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.257 by $0.027.
Is Atara Biotherapeutics overvalued?
According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued.
Does Atara Biotherapeutics pay dividends?
Atara Biotherapeutics does not currently pay dividends.
What is Atara Biotherapeutics’s EPS estimate?
Atara Biotherapeutics’s EPS estimate is -$0.12.
How many shares outstanding does Atara Biotherapeutics have?
Atara Biotherapeutics has 120,416,140 shares outstanding.
What happened to Atara Biotherapeutics’s price movement after its last earnings report?
Atara Biotherapeutics reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.257. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of Atara Biotherapeutics?
Among the largest hedge funds holding Atara Biotherapeutics’s share is Wexford Capital LP. It holds Atara Biotherapeutics’s shares valued at 15K.
---
Atara Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.18 (585.25% Upside)
$4.18 (585.25% Upside)
Blogger Sentiment
Neutral
ATRA Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 16.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $40.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-45.29%
Trailing 12-Months
Company Description
Atara Biotherapeutics
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
---
ATRA Earnings Call
Q3 2023
0:00 / 0:00
---
ATRA Stock 12 Month Forecast
Average Price Target
$4.18
▲(585.25% Upside)
Technical Analysis
Best Analysts Covering ATRA
1 Year
1 Year Success Rate
20/40 ratings generated profit
1 Year Average Return
+16.21%
reiterated a buy rating 10 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +16.21% per trade.
---